TSTickerStarGet alerts
Company alerts/TPST
TPST company alerts

TPST updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for TPST. Subscribe to TPST alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Subscribe for TPST alertsView companies
Official-source feed

Recent TPST alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

Investor eventInvestor relations

Tempest Therapeutics special meeting adjourned; reconvenes November 12, 2026

On October 14, 2026, Tempest Therapeutics, Inc. convened its reconvened special meeting of stockholders, but adjourned the meeting without sufficient votes to approve the Certificate of Amendment proposal. A quorum was present (74.3%), however the proposal, which requires a 75% supermajority vote to replace specified supermajority voting requirements and permit stockholder action by written consent, lacked sufficient votes. The meeting will reconvene on November 12, 2026 at 2:00 p.m. Eastern Time via live webcas...

Read source-backed brief
Company updateOfficial company source

Tempest Therapeutics special meeting adjourned again without sufficient votes on charter amendment proposal

On October 14, 2026, Tempest Therapeutics reconvened its special meeting of stockholders to vote on a proposed Certificate of Amendment to replace supermajority voting requirements and permit stockholder action by written consent, but lacked sufficient votes to approve the proposal. The Company again adjourned the meeting; the meeting will reconvene on November 12, 2026 at 2:00 p.m. Eastern Time via live webcast. The Proposal requires the affirmative vote of at least 75% of votes entitled to be cast.

Read source-backed brief
Debt offeringSEC filing

Tempest Therapeutics files preliminary proxy for November 9, 2026 Annual Meeting; seeks approvals for Lincoln Park equity line and PIPE warrant share issuance

Tempest Therapeutics filed a preliminary proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on November 9, 2026 at 1:00 p.m. Pacific Time, with a record date of October 23, 2026. Stockholders are being asked to elect two Class II directors (Dr. John David Yee and Mr. William Drake Richey), ratify Ernst & Young LLP as the auditor for fiscal 2026, approve the issuance of common stock under the August 13, 2026 Lincoln Park Capital purchase agreement (up to $50.0 million), and approve t...

Read source-backed brief
Debt offeringSEC filing

Tempest Therapeutics files Form D for $7.5M exempt warrant offering

Tempest Therapeutics, Inc. filed a Form D Notice of Exempt Offering of Securities reporting a completed $7,500,000 private placement of pre-funded warrants accompanied by Series C and Series D Common Stock Purchase Warrants, with a combined exercise price of $0.804. The offering was sold to 1 investor under Rule 506(b), with first sale on 2026-09-15 and total remaining to be sold of $0. H.C. Wainwright & Co., LLC acted as placement agent, receiving a $225,000 cash placement fee equal to 7.0% of gross proceeds pl...

Read source-backed brief